Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02728102 · ClinicalTrials.gov registry record · Phase 2
Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
A Phase 2 study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- Phase 2
- Development phase
- 203
- Enrollment target
NCT02728102 is a Phase 2 study that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 203 participants.
The verdict
NCT02728102, a Phase 2 study, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 203 participants
- Enrollment target
Study Summary
The study is designed as a Phase II, multicenter trial of vaccination with Dendritic cell/myeloma fusions with granulocyte macrophage colony-stimulating factor (GM-CSF) adjuvant plus lenalidomide maintenance therapy versus maintenance therapy alone or with GM-CSF following autologous transplant as part of upfront treatment of multiple myeloma (MM). It is hypothesized that the dendritic cell myeloma vaccine will result in improved response in patients with multiple myeloma after autologous Hematopoietic Cell Transplant (HCT).
Interventions
- DRUG Melphalan
- PROCEDURE Leukapheresis
- PROCEDURE Autologous Stem Cell Transplant
- PROCEDURE Tumor Cell Collection
- BIOLOGICAL Myeloma vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2016-07 |
| Est. Completion | 2022-12-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02728102
The ClinicalTrials.gov registry entry for NCT02728102 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 203 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Melphalan is the first listed.
NCT02728102 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02728102 about?
NCT02728102 is a clinical study titled "Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)". The study is designed as a Phase II, multicenter trial of vaccination with Dendritic cell/myeloma fusions with granulocyte macrophage colony-stimulating factor (GM-CSF) adjuvant plus lenalidomide maintenance therapy versus maintenance therapy alone or with GM-CSF following autologous transplant as p...
What is the current status of trial NCT02728102?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 203 participants. The study started on 2016-07. Estimated completion is 2022-12-09.
What interventions are being tested in trial NCT02728102?
The interventions under investigation include: Melphalan (DRUG), Leukapheresis (PROCEDURE), Autologous Stem Cell Transplant (PROCEDURE), Tumor Cell Collection (PROCEDURE), Myeloma vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02728102?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.